131 related articles for article (PubMed ID: 33979959)
1. [Application of aMAP score to assess the risk of hepatocarciongenesis in population of chronic liver disease in primary hospitals].
Li XH; Hao X; Deng YH; Liu XQ; Liu HY; Zhou FY; Fan R; Guo YB; Hou JL
Zhonghua Gan Zang Bing Za Zhi; 2021 Apr; 29(4):332-337. PubMed ID: 33979959
[No Abstract] [Full Text] [Related]
2. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis.
Fan R; Papatheodoridis G; Sun J; Innes H; Toyoda H; Xie Q; Mo S; Sypsa V; Guha IN; Kumada T; Niu J; Dalekos G; Yasuda S; Barnes E; Lian J; Suri V; Idilman R; Barclay ST; Dou X; Berg T; Hayes PC; Flaherty JF; Zhou Y; Zhang Z; Buti M; Hutchinson SJ; Guo Y; Calleja JL; Lin L; Zhao L; Chen Y; Janssen HLA; Zhu C; Shi L; Tang X; Gaggar A; Wei L; Jia J; Irving WL; Johnson PJ; Lampertico P; Hou J
J Hepatol; 2020 Dec; 73(6):1368-1378. PubMed ID: 32707225
[TBL] [Abstract][Full Text] [Related]
3. Novel, high accuracy models for hepatocellular carcinoma prediction based on longitudinal data and cell-free DNA signatures.
Fan R; Chen L; Zhao S; Yang H; Li Z; Qian Y; Ma H; Liu X; Wang C; Liang X; Bai J; Xie J; Fan X; Xie Q; Hao X; Wang C; Yang S; Gao Y; Bai H; Dou X; Liu J; Wu L; Jiang G; Xia Q; Zheng D; Rao H; Xia J; Shang J; Gao P; Xie D; Yu Y; Yang Y; Gao H; Liu Y; Sun A; Jiang Y; Yu Y; Niu J; Sun J; Wang H; Hou J
J Hepatol; 2023 Oct; 79(4):933-944. PubMed ID: 37302583
[TBL] [Abstract][Full Text] [Related]
4. [Higher proportion of hepatitis B-related hepatocellular carcinoma combined with metabolic diseases in patients receiving antiviral therapy].
Zhao Z; Wang KF; Chen L; You QH; Wu YY; Sun J
Zhonghua Gan Zang Bing Za Zhi; 2021 Apr; 29(4):344-349. PubMed ID: 33979961
[No Abstract] [Full Text] [Related]
5. External Validation of aMAP Hepatocellular Carcinoma Risk Score in Patients With Chronic Hepatitis B-Related Cirrhosis Receiving ETV or TDF Therapy.
Gui H; Huang Y; Zhao G; Chen L; Cai W; Wang H; Guo Q; Xie Q
Front Med (Lausanne); 2021; 8():677920. PubMed ID: 34422855
[No Abstract] [Full Text] [Related]
6. Influence of Metabolic Risk Factors on Risk of Hepatocellular Carcinoma and Liver-Related Death in Men With Chronic Hepatitis B: A Large Cohort Study.
Yu MW; Lin CL; Liu CJ; Yang SH; Tseng YL; Wu CF
Gastroenterology; 2017 Oct; 153(4):1006-1017.e5. PubMed ID: 28711626
[TBL] [Abstract][Full Text] [Related]
7. Prediction of late recurrence after radiofrequency ablation of HBV-related hepatocellular carcinoma with the age-male-albumin-bilirubin-platelets (aMAP) risk score: a multicenter study.
Xin Y; Zhang X; Yang Y; Chen Y; Wang Y; Zhou X; Li X
J Gastrointest Oncol; 2021 Dec; 12(6):2930-2942. PubMed ID: 35070419
[TBL] [Abstract][Full Text] [Related]
8. The aMAP score predicts long-term outcomes after resection of hepatocellular carcinoma: a multi-institutional analysis.
Tsilimigras DI; Endo Y; Ratti F; Marques HP; Cauchy F; Lam V; Poultsides GA; Popescu I; Alexandrescu S; Martel G; Kitago M; Guglielmi A; Hugh T; Aldrighetti L; Gleisner A; Shen F; Endo I; Pawlik TM
HPB (Oxford); 2024 Apr; 26(4):541-547. PubMed ID: 38218690
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of aMAP Risk Score for Predicting Recurrence after Curative Treatment for Hepatocellular Carcinoma within Milan Criteria.
Ohama H; Hiraoka A; Tada F; Kato K; Fukunishi Y; Yanagihara E; Kato M; Saneto H; Izumoto H; Ueki H; Yoshino T; Kitahata S; Kawamura T; Kuroda T; Suga Y; Miyata H; Hirooka M; Abe M; Matsuura B; Ninomiya T; Hiasa Y
Oncology; 2023; 101(9):575-583. PubMed ID: 37459848
[TBL] [Abstract][Full Text] [Related]
10. aMAP score prediction of hepatocellular carcinoma occurrence and incidence-free rate after a sustained virologic response in chronic hepatitis C.
Yamashita Y; Joshita S; Sugiura A; Yamazaki T; Kobayashi H; Wakabayashi SI; Yamada Y; Shibata S; Kunimoto H; Iwadare T; Matsumura M; Miyabayashi C; Okumura T; Ozawa S; Nozawa Y; Kobayashi N; Komatsu M; Fujimori N; Saito H; Umemura T
Hepatol Res; 2021 Sep; 51(9):933-942. PubMed ID: 34216422
[TBL] [Abstract][Full Text] [Related]
11. A case-control study of hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Henan, China.
Zhang JY; Dai M; Wang X; Lu WQ; Li DS; Zhang MX; Wang KJ; Dai LP; Han SG; Zhou YF; Zhuang H
Int J Epidemiol; 1998 Aug; 27(4):574-8. PubMed ID: 9758109
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B Virus Combo Mutations Improve the Prediction and Active Prophylaxis of Hepatocellular Carcinoma: A Clinic-Based Cohort Study.
Yin J; Wang J; Pu R; Xin H; Li Z; Han X; Ding Y; Du Y; Liu W; Deng Y; Ji X; Wu M; Yu M; Zhang H; Wang H; Thompson TC; Ni W; Cao G
Cancer Prev Res (Phila); 2015 Oct; 8(10):978-88. PubMed ID: 26290395
[TBL] [Abstract][Full Text] [Related]
13. Diabetes mellitus, metabolic syndrome and obesity are not significant risk factors for hepatocellular carcinoma in an HBV- and HCV-endemic area of Southern Taiwan.
Chen CT; Chen JY; Wang JH; Chang KC; Tseng PL; Kee KM; Chen PF; Tsai LS; Chen SC; Lin SC; Lu SN
Kaohsiung J Med Sci; 2013 Aug; 29(8):451-9. PubMed ID: 23906236
[TBL] [Abstract][Full Text] [Related]
14. Non-invasive tests for liver disease severity and the hepatocellular carcinoma risk in chronic hepatitis B patients with low-level viremia.
Paik N; Sinn DH; Lee JH; Oh IS; Kim JH; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Liver Int; 2018 Jan; 38(1):68-75. PubMed ID: 28581248
[TBL] [Abstract][Full Text] [Related]
15. Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis.
Yang HI; Tseng TC; Liu J; Lee MH; Liu CJ; Su TH; Batrla-Utermann R; Chan HL; Kao JH; Chen CJ
Clin Gastroenterol Hepatol; 2016 Mar; 14(3):461-468.e2. PubMed ID: 26598229
[TBL] [Abstract][Full Text] [Related]
16. High Level of Hepatitis B Core-Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load.
Tseng TC; Liu CJ; Hsu CY; Hong CM; Su TH; Yang WT; Chen CL; Yang HC; Huang YT; Fang-Tzu Kuo S; Liu CH; Chen PJ; Chen DS; Kao JH
Gastroenterology; 2019 Dec; 157(6):1518-1529.e3. PubMed ID: 31470004
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the aMAP score for hepatocellular carcinoma surveillance: a realistic opportunity to risk stratify.
Johnson PJ; Innes H; Hughes DM; Kalyuzhnyy A; Kumada T; Toyoda H
Br J Cancer; 2022 Oct; 127(7):1263-1269. PubMed ID: 35798825
[TBL] [Abstract][Full Text] [Related]
18. Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B.
Chan AW; Wong GL; Chan HY; Tong JH; Yu YH; Choi PC; Chan HL; To KF; Wong VW
J Gastroenterol Hepatol; 2017 Mar; 32(3):667-676. PubMed ID: 27547913
[TBL] [Abstract][Full Text] [Related]
19. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles.
Lee MH; Yang HI; Liu J; Batrla-Utermann R; Jen CL; Iloeje UH; Lu SN; You SL; Wang LY; Chen CJ;
Hepatology; 2013 Aug; 58(2):546-54. PubMed ID: 23504622
[TBL] [Abstract][Full Text] [Related]
20. Development of Risk Prediction Model for Hepatocellular Carcinoma Progression of Indeterminate Nodules in Hepatitis B Virus-Related Cirrhotic Liver.
Cho HJ; Kim B; Lee JD; Kang DR; Kim JK; Lee JH; Shin SJ; Lee KM; Yoo BM; Lee KJ; Kim SS; Cheong JY; Cho SW
Am J Gastroenterol; 2017 Mar; 112(3):460-470. PubMed ID: 27779194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
